MYCN and prostate carcinoma: In prostate cancer, the N-MYC oncoprotein plays a critical role in driving therapy refractory neuroendocrine prostate cancer (NEPC) and N-MYC overexpression can induce both PCA and NEPC from a common epithelial precursor11–13, 27.